KING OF PRUSSIA, Pa., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Aspire Bariatrics, Inc., a commercial-stage medical device company, announced today two abstract presentations will be delivered on the Company’s AspireAssist® at ObesityWeek 2017 Conference, the combined annual meetings for the American Society for Metabolic & Bariatric Surgery (ASMBS) and The Obesity Society (TOS), held in Washington D.C. from October 29 – November 2, 2017.
Presentation Details
“Aspiration Therapy as a Tool to Treat Obesity: One to Four Year Results in a 160-Patient Multi-Center Post-Market Registry Study,” will be given by Evzen Machytka, MD PhD on November 1.
- Post market observational study at five centers; 160 patients
- Mean baseline BMI was 44.9 kg/m2 (range: 35.0-73.8 kg/m2)
- Conclusion: Mean percent weight-loss for patients who completed Year 1 of therapy was 19.3%, while mean percent excess weight-loss was 48.3%. Mean weight loss was maintained or increased through Year 4 of the study. The study concluded the AspireAssist System is a safe, durable, effective durable weight management therapy for people with Class II and Class III obesity and even in people with “super obesity” (BMI ≥55.0 kg/m2).
“A Comparative 100-Participant 5-Year Study of Aspiration Therapy (AT) vs Roux-en-Y (RYGB) Gastric Bypass: First Year Results,” will be given by Erik B Wilson on November 2.
- Prospective study comparing safety, efficacy, and economics of patients who chose to undergo either RYGB or AT.
- A total of 56 patients enrolled in the AT Group (BMI = 42.6+7.5 kg/m2) with 50 patients in the RYGB Group (BMI = 41.1+5.0 kg/m2). The two arms were matched in age and baseline health status.
- Conclusion: One-year results show aspiration therapy provides approximately 2/3 of the weight loss of RYGB, but also reveals fewer and less severe adverse events requiring additional interventions.
“Aspiration Therapy with the AspireAssist System has been proven to be a safe, durable, effective weight management therapy for people with Class II and Class III obesity,” said Kathy Crothall, PhD, President & CEO of Aspire Bariatrics. “We are looking forward to the presentation of these two important studies that demonstrate compelling data and patient experiences in support of weight-loss therapy with our AspireAssist and to participating in this year’s ObesityWeek.”
About Aspire Bariatrics, Inc.
Aspire Bariatrics is a commercial-stage medical device company with a minimally-invasive, endoscopic device, the AspireAssist®, to treat obesity. In June 2016, the Company received premarket approval (PMA) from the FDA. AspireAssist Therapy is an alternative to bariatric surgery, providing comparable weight loss, but with far better safety, complete reversibility, and at a significantly lower cost than bariatric surgery. The therapy provides a holistic approach to patient development of improved eating behaviors, reflected in significant improvement in quality of life and high satisfaction with the therapy. www.aspirebariatrics.com.
About the AspireAssist
Approved by the FDA in 2016, the AspireAssist offers an alternative therapy for patients with BMI 35 to 55 who decline bariatric surgery, or are not candidates for surgery. The AspireAssist works through a dual mechanism of action, serving as a tool to help patients learn slow and mindful eating, while preventing about 30% of calories from being absorbed by the body. The device is placed in a simple 15-minute PEG procedure, and offers excellent weight loss with an exceptionally low incidence of complications.
Contact for Investors and Media
Kathy Crothall, PhD
President and CEO
(610) 590-1568
kathy.crothall@aspirebariatrics.com